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7 ABSTRACT: Three inorganic cocrystal (ICC) forms of carbamazepine
8 (CBZ) have been synthesized, and their crystal structures are described.
9 [Na(CBZ)4(MeOH)][I]·H2O, [Na(CBZ)5][I3], and [Na(CBZ)5]-
10 [C13H10N][IBr2]2 are the ﬁrst CBZ structures that contain metal
11 cations, and the latter example also contains acridinium, which is a
12 known metabolite of CBZ. All three Na complexes have distorted square
13 pyramidal NaO5 coordination geometries but diﬀerent conformations of
14 the four basal ligands and diﬀerent hydrogen bonding interactions for
15 the apical ligand. The hydrogen bonded synthons that have been
16 identiﬁed for other species that contain neutral CBZ molecules are
17 absent in all these Na containing ICC phases and are replaced by Na−O
18 dative bonds. However, previously identiﬁed nonpolar supramolecular
19 constructs in the form of stacks and dimers are shared with other CBZ
20 containing structures.
21 ■ INTRODUCTION
22 Carbemazepine (CBZ) is the anticonvulsant drug used in the
23 treatment of epilepsy that has become one of the best known
24 model compounds used in solid state form identiﬁcation and
25 characterization studies. It is attractive because it is a
26 molecularly simple active pharmaceutical ingredient (API)
27 with a nonpolar backbone and a single polar amide
28 functionality that is available for hydrogen bonding. Such
29 studies have led to date to ﬁve polymorphic crystalline phases
30 of CBZ being described,1−3 together with the structures of over
31 50 cocrystalline or solvate forms. Approximately half of the
32 crystal coformers used with CBZ are neutral carboxylic acids4−7
33 with organic solvates making up the next biggest grouping.7−10
34 Supramolecular structural similarities throughout these species
35 have been described by Gelbrich and Hursthouse and further
36 commented on by others.4,11 Although numerous, most of the
37 known phases of CBZ are thus somewhat homogeneous with
38 respect to general chemical type. Some alternative formulations
39 have been attempted. For instance, although amide function-
40 alities are traditionally thought of as being nonionizable under
41 normal chemical conditions,12 salt forms of CBZ with
42 protonation at the amide O atom have recently been reported.
43 Perumalla and Sun described a hydrochloride salt form,13
44 Frampton and co-workers described the methanesulfonate salt
45 form,14 and we have described a series of ﬁve [CBZ(H)][X]·
46 nH2O (X = Cl or Br, n = 0 or 1) salts.
15 This latter work also
47 described how exposing carbamazepine hydrochloride to
48 atmospheric water led to the formation of a hydronium salt,
49 [H3O][Cl]·2CBZ·2H2O. Although this can be described as a
50 salt form, it contains neutral CBZ rather than protonated
51CBZ(H) and can thus perhaps be best thought of as a cocrystal
52of hydronium chloride and CBZ. Recently the term ionic
53cocrystal (ICC) has been popularized for such formulations to
54diﬀerentiate them from the more usual API cocrystal case
55where both the coformers are neutral organic molecules.16,17
56Structurally similar species with neutral organic molecules
57cocrystallized with cations and anions are of course well-known
58in metal coordination chemistry and elsewhere, where they are
59typically referred to as dipole (or solvent) separated ion pair
60complexes.18−22 Similar species are also known with
61ammonium ions replacing metal ions.23−25 The novelty of
62the ICC terminology lies in the context of typically
63pharmaceutically active organic species and the deliberate
64crystal engineering of their structures to replace organic to
65organic intermolecular interactions with ionic contacts. Despite
66the recent coining of the term, such API-based ICC species can
67be found in the historical literature, including a structural report
68on two forms of CBZ, namely [NH4][X][CBZ] where X = Cl
69or Br.26 With ammonium and hydronium halide complexes of
70CBZ being known and with the well-known occurrence of
71donor separated ion pair species throughout main group metal
72coordination chemistry, we decided to investigate the
73possibility of forming ICC forms of CBZ with s-block metal
74salts. Described herein is the synthesis and characterization of
75three such species, [Na(CBZ)4(MeOH)][I]·H2O, [Na-
76(CBZ)5][I3], and [Na(CBZ)5][C13H10N][IBr2]2.
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77 ■ EXPERIMENTAL SECTION
78 Single crystal X-ray diﬀraction (SXD) measurements on the acridine
79 I2Br salt were carried out by the National Crystallography Service.
27
80 All other crystallographic measurements were performed locally using
81 Oxford Diﬀraction instruments. Structural solution and reﬁnement
82 against F2 to convergence were performed using programs from the
83 SHELX suite.28 Hydrogen atoms bound to carbon were placed in
84 idealized positions and reﬁned in riding modes. Where possible, H
85 atoms bound to nitrogen or oxygen were placed as found in diﬀerence
86 Fourier syntheses and reﬁned isotropically but with N−H bond length
87 restraints for CBZ containing species. For the structure of [Na-
88 (CBZ)5][C13H10N][IBr2]2, poor crystal quality and a disordered CBZ
89 ligand resulted in a relatively low quality structure. Here all H atoms
90 were generated in idealized positions and allowed to ride on their
91 parent atoms. Selected crystallographic and reﬁnement parameters are
t1 92 given in Table 1 for the Na containing species and in the Supporting
93 Information for the others.
94 FTIR measurements were made on crushed solid samples and with
95 an A2 Technologies ATR instrument.
96 Synthesis of [Na(CBZ)4(MeOH)][I]·H2O, Method 1. A large
97 excess (5.010 g, 33.4 mmol) of sodium iodide and 0.216 g (0.91
98 mmol) of carbamazepine were dissolved in 8 cm3 of methanol. The
99 solution was heated in a water bath until the carbamazepine and
100 sodium iodide had dissolved. Once the solution had cooled to room
101 temperature, 1 cm3 of acetyl chloride was slowly added. A vigorous
102 reaction was observed, and NaI precipitated. This was removed by
103 ﬁltration, and the ﬁltrate was poured into a narrow tube and sealed
104 with paraﬁlm. Small holes were made in the paraﬁlm to aid
105 evaporation. Suitable crystals grew after approximately 7 days. IR
106 νmax 3458, 3323, 3266, 3197, 1652, 1575, 1490, 1418, 806, 764 cm
−1.
107 Synthesis of [Na(CBZ)4(MeOH)][I]·H2O, Method 2. A large
108 excess (5.306 g, 35.4 mmol) of sodium iodide and 0.264 g (1.12
109 mmol) of carbamazepine were dissolved in 8 cm3 of methanol. The
110 solution was heated in a water bath until both the carbamazepine and
111 sodium iodide had dissolved. The test tube was sealed with paraﬁlm
112 and left to cool to room temperature. Small holes were made in the
113 paraﬁlm to aid evaporation. Suitable crystals grew after approximately
114 2 days. SXD and IR spectroscopy showed these to be identical to the
115 product isolated by method 1.
116Synthesis of [Na(CBZ5)][I3]. A large excess (5.515 g, 36.8 mmol)
117of sodium iodide and 0.246 g (1.04 mmol) of carbamazepine were
118dissolved in 8 cm3 of ethanol. The solution was heated in a water bath
119until both the carbamazepine and sodium iodide had dissolved. Once
120the solution had cooled to room temperature, 1 cm3 of acetyl bromide
121was slowly added. A vigorous reaction was observed, and an inorganic
122solid precipitated. This was removed by ﬁltration, and the solution was
123left in a narrow tube for approximately 1 month, after which time
124suitable crystals had formed. IR νmax 3463, 3434, 3411, 3266, 3194,
1251652, 1569, 1489, 1418, 1394, 808, 763 cm−1.
126Synthesis of Carbamazepine Ammonium Bromide. Ammo-
127nium bromide (0.043 g, 0.44 mmol) and 0.209 g (0.88 mmol) of
128carbamazepine were dissolved in 4 cm3 of methanol. The solution was
129heated in a water bath until both ammonium bromide and
130carbamazepine had dissolved. Once the solution had cooled to room
131temperature, 1 cm3 of acetyl bromide was slowly added. A vigorous
132reaction was observed. The test tube was sealed with paraﬁlm. Small
133holes were made in the paraﬁlm to aid evaporation. After 23 days,
134crystals had formed and were collected for SXD analysis.
135Synthesis of Acridinium I2X Species, [C13H10N][I2X], X = Cl or
136Br. Potassium iodide (0.078 g, 0.47 mmol) and 0.221 g (0.94 mmol)
137of carbamazepine were dissolved in 8 cm3 of methanol. The solution
138was heated in a water bath until both the potassium iodide and
139carbamazepine had dissolved. Once the solution had cooled to room
140temperature, 1 cm3 of acetyl chloride was slowly added. A vigorous
141reaction was observed, and a solid formed, which was removed by
142ﬁltration. After slow evaporation overnight, colorless crystals of
143carbamazepine hydrochloride form II were obtained.15 Leaving the
144solution for a further 3 days resulted in darkening of the solution and
145the deposition of red crystals. These have been characterized as
146[acridinium][I2Cl]. The same acridinium species was obtained when
147CsI was used in place of KI. Replacing MI with NH4I and using acetyl
148bromide rather than acetyl chloride gave dark blue crystals of
149[acridinium][I2Br].
150Synthesis of [Na(CBZ)5][C13H10N] [IBr2]2. Sodium iodide (0.071
151g, 0.43 mmol) and 0.224 g (0.95 mmol) of carbamazepine were
152dissolved in 4 cm3 of methanol. The solution was heated in a water
153bath until both sodium iodide and carbamazepine had dissolved. Once
154the solution had cooled to room temperature, 1 cm3 of hydrobromic
155acid was added. The test tube was sealed with paraﬁlm. Small holes
156were made in the paraﬁlm to aid evaporation. Yellow crystalline
Table 1. Selected Crystallographic and Reﬁnement Parameters for Na Complexes
compound [Na(CBZ)4(MeOH)][I]·H2O [Na(CBZ)5][I3] [Na(CBZ)5][C13H10N] [IBr2]2
formula C61H54IN8NaO6 C75H60I3N10NaO5 C88H70Br4I2N11NaO5
formula wt 1145.01 1585.02 1957.98
cryst syst monoclinic monoclinic triclinic
space group C2 P21/n P1̅
λ, Å 1.5418 0.71073 0.71073
a, Å 27.3789(19) 16.1230(6) 10.2171(5)
b, Å 6.8157(2) 11.2270(4) 14.4369(6)
c, Å 20.8598(14) 36.8726(16) 27.5476(12)
α, deg 90 90 91.841(3)
β, deg 134.626 (12) 91.165(3) 96.689(4)
γ, deg 90 90 90.972(4)
vol, Å3 2770.4(3) 6673.0(4) 4032.7(3)
temp, K 123(2) 153(2) 123(20)
Z 2 4 2
reﬂns collected 5761 32950 28299
2θ max, deg 146.1 54.0 50.0
reﬂns unique 4078 13309 14166
reﬂns obsd 4037 7205 8248
Rint 0.0267 0.0732 0.0708
GOF 1.078 1.029 1.075
R[I > 2σ(I)], F 0.0364 0.0612 0.0847
Rw, F2 0.0957 0.1019 0.2027
max/min electron density, e Å−3 1.581/−0.685 0.646/−0.750 1.351/−1.168
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157 material was deposited after approximately 4 days. IR νmax 3421, 3315,
158 1601,1567, 1487, 1455, 1435, 804, 769, 746, 726 cm−1.
159 ■ RESULTS AND DISCUSSION
160 The structures of two types of species that can be described as
161 ICC complexes are known for CBZ, the ammonium containing
162 isostructural species [NH4][X][CBZ] where X = Cl or Br and
163 the hydronium [H3O][Cl]·2CBZ·2H2O.
15,26 Neither type
164 contains a metal ion, so the initial goal of this work was to
165 introduce a pharmaceutically acceptable metal cation such as
166 Na+. The known CBZ ICC species were not prepared by
167 straightforward cocrystallization of the salt with CBZ. The
168 ammonium species were prepared by Reck and Thiel in the
169 presence of a surfactant,26 while the hydronium species
170 originated from slow addition of atmospheric water to a
171 reactive salt form of CBZ, namely, the oxygen protonated salt
172 [CBZ(H)][Cl].15 Initially, we attempted to form CBZ ICC
173 complexes by simply cocrystallizing methanolic solutions of
174 CBZ with aqueous solutions of a wide variety of simple s-block
175 metal salts. None of these attempts were successful; nor was a
176 similar attempt to prepare [NH4][X][CBZ] in the absence of
177 surfactant. It was thus decided to attempt an adaptation of the
178 route that gave the hydronium species. This involved addition
179 of acetyl halide to methanol solutions of the API to give in situ
180 generation of nonaqueous HCl or HBr. In the absence of other
181 ions, this is known to give protonated CBZ, which crystallizes
182 as halide salts.13,15 However, herein the methanolic CBZ
183 solutions also contained additional simple salts (usually iodides
184 because these were found to be more soluble than other
185 halides) initially in very high concentrations in an attempt to
186 force the inclusion of ions in the ﬁnal product. This approach
187 allowed the isolation of two ICC forms of CBZ with Na. Single
188 crystal diﬀraction showed these to be [Na(CBZ)4(MeOH)][I]·
189 H2O and [Na(CBZ)5][I3], see Experimental Section for
190 preparative details. Despite the great eﬀorts previously
191 expended on preparing novel forms of CBZ, there are no
192 structural reports of CBZ species that contain metal ions in the
193 CCDC.29 A similar approach utilizing acetyl bromide also
194 allowed [NH4][Br][CBZ] to be isolated and analyzed without
195 the use of surfactant.
196 The structure of [Na(CBZ)4(MeOH)][I]·H2O has crystallo-
197 graphically imposed C2 symmetry, and both [Na-
198 (CBZ)4(MeOH)][I]·H2O and [Na(CBZ)5][I3] feature dis-
199 torted square pyramidal NaO5 cores (τ = 0.41 and 0.28 for
200 [Na(CBZ)4(MeOH)][I]·H2O and [Na(CBZ)5][I3], respec-
201 tively, where τ = 0 indicates ideal square pyramidal geometry
f1 202 and τ = 1 corresponds to trigonal bipyramidal),30 see Figures 1
f2 203 and 2. In both cases, the Na ion is raised slightly above the basal
204 plane described by the four O donor atoms from the CBZ
205 ligands (by 0.453(3) and 0.574(3) Å, respectively), with the
206 apical coordination site being occupied by a disordered MeOH
207 ligand in [Na(CBZ)4(MeOH)][I]·H2O and by a ﬁfth CBZ
208 ligand in [Na(CBZ)5][I3]. Na−O bond lengths in the more
209 sterically crowded [Na(CBZ)5] cation are somewhat elongated
210 compared with those of the [Na(CBZ)4(MeOH)] ion. The
211 range of basal Na−O distances is thus 2.326(4) to 2.403(4) Å
212 for [Na(CBZ)5] and 2.317(3) to 2.366(3) Å for [Na-
213 (CBZ)4(MeOH)]. In both species, the apical Na−O bond is
214 the shortest, with this being a more signiﬁcant diﬀerence for the
215 coordinated MeOH (2.307(4) and 2.258(9) Å for [Na(CBZ)5]
216 and [Na(CBZ)4(MeOH)], respectively). All four CBZ ligands
217 of the [Na(CBZ)4(MeOH)] ion are orientated so that their
218 azepine rings lie below the complex’s basal plane, with one trans
219pair of ligands signiﬁcantly more below the plane than the other
220mutually trans pair (compare 145.33(19)° and 170.0(2)° for
221O1−Na1−O1′ and O2−Na1−O2′ respectively, ′ = 1 − x, y, 1
222− z).
223The four basal CBZ ligands of the [Na(CBZ)5] ion adopt a
224diﬀerent conformation, with three azepine rings below the basal
225 f3plane and one (that containing N1) above the plane, see Figure
226 f33. Despite this conformational diﬀerence, intramolecular
227hydrogen bonding between the four basal CBZ ligands is
228similar for the two complexes, Figures 1 and 2. In each
229complex, each of the amide NH2 groups of the four basal CBZ
230ligands donates a single intramolecular hydrogen bond to the
231amide O atom acceptor of the neighboring basal CBZ ligand.
232The second H atom of these four NH2 groups does not form a
233hydrogen bonding interaction. The apical CBZ ligand of the
234[Na(CBZ)5] cation does not take part in any classical hydrogen
235bonds, but its NH2 group is orientated toward the oleﬁn
236backbone of the unique azepine ring that lies above the basal
237plane (H to CC centroid is 2.80 Å). In contrast, the apical
238MeOH ligand of [Na(CBZ)4(MeOH)] simply donates a O−
Figure 1. Molecular structure of [Na(CBZ)4(MeOH)][I]·H2O.
Disorder in the solvent and all nonamide hydrogen atoms have been
omitted for clarity. Here and elsewhere, hydrogen bonds are shown as
light blue lines.
Figure 2. Molecular structure of the cation in [Na(CBZ)5][I3].
Nonamide hydrogen atoms have been omitted for clarity.
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239 H···O hydrogen bond to the water solvate. Both MeOH and
240 water positions are disordered about the crystallographic 2-fold
241 rotation axis, and thus discussion of the geometric details of
242 these groups is not warranted. This diﬀerence in hydrogen
243 bonding between the two species may contribute to the
244 diﬀerent conformations of the basal Na(CBZ)4 units.
245 Examination of the bond lengths of the amide groups and
246 comparison with literature compilations of equivalent data
247 shows that all the CBZ ligands of these two Na complexes have
248 CO and C−N bond lengths that lie within the ranges
249 normally seen for neutral CBZ species.14,15 This indicates that
250 complexation to Na does not greatly alter the ligands’ internal
251 geometries. However, the geometry of the apical CBZ ligand of
252 the [Na(CBZ)5] cation does diﬀer subtly from the geometries
253 of the other coordinated CBZ ligands. The CO length of the
254 apical ligand is somewhat shorter than the others (compare
255 1.223(7) with a range of 1.240(6)−1.251(6) Å) and both C−N
256 distances of the apical ligand are somewhat longer than those of
257 the other ligands (compare 1.370(8) and 1.378(7) Å for C−
258 NH2 and C−NR2 with ranges of 1.335(7)−1.344(8) and
259 1.354(7)−1.369(7) Å).
260 Most of the cocrystallization experiments attempted simply
261 returned the starting materials or CBZ dihydrate or previously
262 known hydrogen halide salts of CBZ as the sole products. The
263 color of some experiments, especially those with low pH, was
264 observed to darken with time. Similar darkening of samples
265 with time was seen in solutions of protonated CBZ(H) salt
266 forms.15 This was attributed to the decomposition of CBZ to
267 acridine, and this is now conﬁrmed by the isolation and crystal
268 structure determination of two acridinium salt species,
269 [C13H10N][I2X], X = Cl or Br. The structures are included in
270 the Supporting Information as rare examples of crystallo-
271 graphically well ordered [I2X]n species.
31−33 Although the
272 transformation from CBZ to acridine is rather unintuitive, a
273 variety of experimental conditions have been reported to induce
274 this decomposition. Indeed acridine is a known metabolite of
275 CBZ.34−37 On attempting to replace in situ generation of acid
276 with a simple addition of aqueous HBr, a third Na ICC
277 complex was obtained, [Na(CBZ)5][C13H10N][IBr2]2. That
278 this species contains both CBZ and acridinium makes it of
f4 279 enhanced interest, see Figure 4.
280 The [Na(CBZ)5] cation in [Na(CBZ)5][C13H10N][IBr2]2 is
281 similar to that in [Na(CBZ)5][I3] in that the NaO5 core has a
282 near square pyramidal geometry (τ = 0.11, Na1 raised 0.395(5)
283 Å from the plane deﬁned by the four basal O atoms). Another
284similarity is that one of the four basal CBZ ligands is again
285orientated with its azepine ring above the basal plane deﬁned by
286the four O atoms and the other three azepine rings lie below
287this plane. However, one of these basal CBZ ligands is
288disordered such that a minor conformation is also present in
289the crystal, and this has two azepine rings above the basal plane
290and two below it. As with both the other Na complexes, the
291amide groups of the four basal CBZ ligands form intra-
292molecular N−H···O hydrogen bonds with their neighboring
293CBZ ligands. The NH2 group of the ﬁfth apical CBZ ligand
294behaves diﬀerently from that in [Na(CBZ)5][I3]. Rather than a
295weak interaction with the pi system of the azepine ring that is
296raised above the basal plane, here the amine group forms a
297classical N−H···O interaction with the O atom of the raised
298ligand. Meanwhile, the O atom of the apical CBZ ligand is
299involved in a strong hydrogen bond with the formally positively
300charged N−H group of the acridinium cation. Thus, the two
301cations [Na(CBZ)5] and [C13H10N] are bound tightly together.
302None of the anions in any of the three Na species described
303interact with polar groups of the cations. In all cases, only C−
304H···X (X = I or Br) interactions are observed. For
305[Na(CBZ)5][I3] none of these interactions are shorter than
306the sum of van der Waals distances while the other two species
307each make four C−H···X interactions shorter than van der
308Waals distances. Inorganic coordination chemists would thus
309classify all three species as dipole separated ion pair
310complexes.18−22
311ICC forms are of generic interest because they present the
312possibility of generating API containing materials with diﬀerent
313intermolecular bond types from those seen in organic systems,
314and this may allow the chemicophysical properties of APIs to
315be modiﬁed.16,17 Intermolecular interactions and packing in
316CBZ polymorphs and cocrystals have been widely commented
317on in the literature. Two descriptive strands are often used. The
318ﬁrst of these describes the various supramolecular synthons
319found in CBZ species, commonly such synthons are based on
320the hydrogen bonding modes of the amide group. The various
321structures of the CBZ polymorphs are based upon CBZ dimers.
322This dimeric arrangement is often contrasted with a theoretical
323chain structure predicted to be stable and similar to the motif
324found in related amides.38−41 In many cocrystalline forms of
325CBZ, the dimeric motif is retained, commonly with the addition
326 f5of N−H···A hydrogen bonds as shown in Figure 5. An
Figure 3. Cation of [Na(CBZ)5][I3] drawn so as to emphasize the
three down, one up conformation of the apezine rings of the four basal
ligands. The ligand containing N9 is the ﬁfth, apical ligand.
Figure 4. Hydrogen bonded [Na(CBZ)5] and acridinium cation pair
found in the structure of [Na(CBZ)5][C13H10N][IBr2]2. H atoms
bound to C are omitted for clarity.
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327 alternative arrangement is found in phases where the coformer
328 is a carboxylic acid. Here the commonly found motif is a
329 heterodimer with an amide to COOH contact.8,9 A second
330 strand of CBZ structural analysis has looked not just at
331 intermolecular bonding interactions but at supramolecular
332 constructs, that is at any packing motif that is repeated in
333 diﬀerent CBZ phases no matter what the bonding nature of the
334 interaction might be. This approach identiﬁed two dimeric
335 constructs and two stacking constructs that appear in multiple
336 CBZ structures (including the hydrogen bonded dimer
337 discussed above).11
338 Ammonium halide based ICC forms of CBZ have been
339 known for some time. These are the isostructural species
340 [NH4][X][CBZ] where X = Cl and Br.
26 Because the available
341 database structures (VUBCAW and VUBCEA) do not contain
342 information on H atom positions, we have redetermined the
343 structure of [NH4][Br][CBZ] at low temperature. This
344 conﬁrms that [NH4][Br][CBZ] has a CBZ hydrogen bonded
345 dimer motif with further hydrogen bonds from the dimer to
f6 346 both cations and anions, see Figure 6. This is a simple variation
347 on the hydrogen bonding structure common to many organic
348cocrystals of CBZ. The hydronium, [H3O][Cl]·2CBZ·2H2O,
349also retains the hydrogen bonded CBZ dimer although CBZ
350salt forms with O atom protonated amide groups do not.15
351Furthermore, the [NH4][X][CBZ] species were included in
352Gelbrich and Hursthouse’s initial work on supramolecular
353constructs in CBZ.11 In this analysis, both have entirely
354unexceptional packing features with structures that contain the
355common “translational stack” motif as well as the hydrogen
356bonded dimer (supramolecular constructs A and C in ref 11).
357Thus, despite containing charged ions, the ICC structures of
358[NH4][X][CBZ] are not obviously diﬀerent from the
359structures of nonionic CBZ cocrystals. However, the three Na
360containing ICC forms of CBZ described herein do have
361signiﬁcant structural diﬀerences from the CBZ cocrystals
362previously described. The hydrogen bonded CBZ dimer is
363now absent. Complexation to the Na center requires the CBZ
364ligands to point inward to the common center and constrains
365the homoleptic CBZ NH···O interactions such that they
366connect only to CBZ ligands bound to the shared Na center.
367Note that although the observed structures do not contain CBZ
368dimers, such an arrangement is entirely possible. The structures
369of ammonium and alkali metal salts of the same anions are
370often isostructural;42−45 thus a situation where the “NaI”
371species adopt structures akin to that of [NH4][Br][CBZ] is
372conceivable. Although the three Na complexes do not adopt the
373same hydrogen bonded supramolecular synthons as other CBZ
374species, they do adopt the nonpolar (or shape-based)
375supramolecular constructs previously identiﬁed.11 Both trans-
376lational stacks and dimeric examples can be identiﬁed, as
377 f7f8illustrated in Figures 7 and 8.
Figure 5. Representation of the CBZ hydrogen bonded dimer motif.
When present, S is a hydrogen bond acceptor in the form of a solvent
molecule or a cocrystal conformer.
Figure 6. Part of the hydrogen bonding motif found in the structure of
[NH4][Br][CBZ]. Bromide ions drawn as brown spheres.
Figure 7. Translational stack of CBZ molecules found in the structure
of [Na(CBZ)4(MeOH)][I]·H2O. This is supramolecular construct A
in ref 11. In this case, the translation is along the crystallographic b axis
and hence along the Na−O(MeOH) molecular axis.
Figure 8. Close packed dimer of CBZ molecules found in the structure
of [Na(CBZ)][I3]. This is supramolecular construct B in ref 11.
Similar interactions can be found in the structure of [Na(CBZ)5]-
[C13H10N][IBr2]2.
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378 ■ CONCLUSION
379 The ﬁrst structures of metal containing forms of CBZ have
380 been synthesized and crystallographically characterized. These
381 three Na complexes can be described as ionic cocrystals.
382 Synthesis at low pH was found to be advantageous. Unlike the
383 previously described ammonium halide and hydronium
384 chloride ICC forms of CBZ, these new structures do not
385 show the same intermolecular bonding motifs as other neutral-
386 CBZ containing phases. Instead dative bonds between Na and
387 the O atom of CBZ predominate and, because the halide based
388 anions make only relatively weak C−H···X contacts with the
389 cations, give dipole separated ion pair forms. CBZ to CBZ
390 hydrogen bonding interactions exist solely within the ligand
391 sets of single [Na(CBZ)4(HOMe)] or [Na(CBZ)5] cations.
392 Despite the dramatic change in intermolecular bond type and
393 geometry, the three Na containing CBZ ICC phases still
394 present the previously identiﬁed nonpolar CBZ supramolecular
395 constructs, showing that here at least these shape-based packing
396 motifs are more robust than the polar hydrogen bonded
397 synthons. The change in intermolecular bonding and the high
398 ratio of CBZ to coformer make these ICC forms interesting
399 materials for the study of API form selection.
400 ■ ASSOCIATED CONTENT
401 *S Supporting Information
402 X-ray crystallographic information for [NH4][Br][CBZ] and
403 the acridinium salts with I2Br and I2Cl and crystallographic
404 information ﬁles (CIF) for all six structures. This material is
405 available free of charge via the Internet at http://pubs.acs.org.
406 Crystallographic information ﬁles are also available from the
407 Cambridge Crystallographic Data Center (CCDC) upon
408 request (http://www.ccdc.cam.ac.uk, CCDC deposition num-
409 bers 1023495 to 1023500).
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